Vyvanse Cost in South Dakota: Prices, Insurance, and Savings in 2026

What Vyvanse Actually Costs at South Dakota Pharmacies in 2026

The gap between sticker price and what patients actually pay for Vyvanse in South Dakota is enormous. Takeda's wholesale acquisition cost (WAC) remains approximately $390 per month for a 30-count supply of brand-name Vyvanse capsules [1]. Yet the average cash-pay price across South Dakota retail pharmacies has dropped to roughly $35 per month in 2026, driven almost entirely by the entry of generic lisdexamfetamine in August 2023.

Before generics arrived, patients without insurance routinely paid $350 to $400 out of pocket at Sioux Falls, Rapid City, and Aberdeen pharmacies. The FDA approved the first generic lisdexamfetamine dimesylate capsules in 2023 [2], and multiple manufacturers now compete in the market. That competition compressed retail prices across the state by more than 90%.

Prices still vary by pharmacy. Costco and independent pharmacies in eastern South Dakota tend to price generic lisdexamfetamine between $25 and $40 for a 30-day supply, while some chain pharmacies in western parts of the state may charge $45 to $60 without a discount coupon. Patients filling brand-name Vyvanse without insurance or a savings card will still encounter prices near $390.

One variable that South Dakota patients often overlook: dose strength. All Vyvanse capsule strengths (10 mg through 70 mg) carry the same list price per capsule. A patient titrating from 30 mg to 70 mg will not see a price increase per unit [1]. This differs from medications where higher strengths cost more, and it means dose optimization does not carry an added financial penalty.

South Dakota Medicaid Does Not Cover Vyvanse

South Dakota's Medicaid program does not include Vyvanse or generic lisdexamfetamine on its preferred drug list as of 2026. Patients enrolled in South Dakota Medicaid who need treatment for ADHD are typically directed toward alternative stimulant medications that do carry coverage, such as generic mixed amphetamine salts (Adderall) or generic methylphenidate formulations [3].

The American Academy of Pediatrics (AAP) 2019 Clinical Practice Guideline for ADHD states that "for elementary school-aged children (6 through 11 years of age), the clinician should prescribe FDA-approved medications for ADHD and/or evidence-based parent and/or teacher-administered behavior therapy as treatment" [3]. The guideline does not mandate a specific stimulant, which gives state Medicaid programs discretion to prefer lower-cost agents.

South Dakota Medicaid does allow prior authorization requests. A prescriber can submit documentation showing that a patient failed or experienced intolerable side effects on two or more preferred alternatives. Approval rates for prior authorization of non-preferred stimulants in state Medicaid programs nationally hover around 60% to 70%, according to data from the Medicaid and CHIP Payment and Access Commission (MACPAC) [4]. Patients or caregivers who receive a denial should request the specific denial reason in writing and work with their prescriber to file an appeal within the 30-day window South Dakota allows.

For adults with binge eating disorder (BED), the coverage gap is wider. Vyvanse is the only FDA-approved pharmacotherapy for moderate-to-severe BED [2], which creates a situation where the single approved drug for a condition falls outside the state's formulary. Prescribers treating BED in Medicaid patients may need to document the lack of FDA-approved alternatives when filing prior authorization.

Insurance Coverage for Vyvanse Across South Dakota Plans

Commercial insurance plans available in South Dakota vary widely in how they handle Vyvanse. Avera Health Plans, Sanford Health Plan, and plans sold through the federal marketplace (healthcare.gov) each maintain separate formularies.

Most commercial plans in the state now place generic lisdexamfetamine on Tier 2 (preferred brand or preferred generic), with typical copays ranging from $15 to $50 per month. Brand-name Vyvanse, when covered, usually sits on Tier 3 or a specialty tier, with copays of $60 to $100 or coinsurance of 25% to 40% after deductible.

A 2022 analysis published in JAMA Network Open found that among commercially insured patients with ADHD, mean annual out-of-pocket spending on stimulant medications was $289 (95% CI, $278 to $300), though patients on brand-name long-acting formulations paid significantly more [5]. Generic availability since 2023 has narrowed that gap.

Patients on high-deductible health plans (HDHPs), which are common among South Dakota's self-employed agricultural workforce, may pay full cash price until meeting their deductible. For these patients, filling generic lisdexamfetamine with a GoodRx or RxSaver coupon at a Sioux Falls Walmart or Hy-Vee pharmacy may cost less than running the prescription through insurance during the deductible phase.

Dr. Timothy Wilens, Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital, has noted: "Access to ADHD medications remains one of the most significant barriers to treatment adherence, particularly in states with limited Medicaid formularies" [6]. South Dakota's combination of a restrictive Medicaid formulary and a largely rural population amplifies this barrier.

The Takeda Savings Card and How It Works in South Dakota

Takeda Pharmaceuticals offers a manufacturer savings card for brand-name Vyvanse. Eligible patients with commercial insurance can pay as little as $30 per 30-day prescription fill, with Takeda covering the remaining copay up to a program maximum [1].

Key eligibility requirements for the Takeda Vyvanse savings card:

• The patient must have commercial (private) insurance. Government-funded insurance (Medicaid, Medicare, TRICARE, VA) is excluded by federal anti-kickback statute.
• The card typically resets annually, with a maximum annual benefit that has historically ranged from $3,600 to $7,200.
• The card can only be used at participating retail pharmacies. Most South Dakota chain pharmacies (CVS, Walgreens, Lewis Drug, Hy-Vee) accept manufacturer copay cards.

One operational detail: the savings card applies only to brand-name Vyvanse, not to generic lisdexamfetamine. If a pharmacist dispenses the generic (as South Dakota's substitution law permits unless the prescriber writes "DAW" or "Dispense as Written"), the savings card will not process. Patients who want to use the card must ensure the prescription is filled as brand-name Vyvanse.

For commercially insured patients whose plan already covers generic lisdexamfetamine at a low copay ($15 to $30), the savings card may offer little additional benefit. It becomes most valuable for patients whose plans either do not cover Vyvanse at all or place it on a high-cost specialty tier.

Compounded Lisdexamfetamine in South Dakota: Legal and Available

Compounded lisdexamfetamine is legal in South Dakota through licensed 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacist may compound a medication for an individual patient based on a valid prescription, provided the compounded drug is not essentially a copy of a commercially available product [7].

The practical application here is specific. Compounded lisdexamfetamine can be prepared in dosage forms or strengths not commercially available (for example, a liquid suspension for a child who cannot swallow capsules, or an intermediate dose between commercially available strengths). However, a 503A pharmacy cannot simply compound a generic lisdexamfetamine 30 mg capsule to undercut the price of the commercially available product.

South Dakota has several licensed 503A compounding pharmacies, primarily concentrated in Sioux Falls and Rapid City. The South Dakota Board of Pharmacy oversees these facilities [8]. Patients considering compounded lisdexamfetamine should confirm that the pharmacy holds a valid state compounding license and that the prescription specifies a clinical reason for the compounded formulation (such as a non-standard dose or an allergy to an inactive ingredient in the commercial product).

Pricing for compounded lisdexamfetamine varies by pharmacy. Some South Dakota compounding pharmacies advertise rates comparable to or lower than generic retail pricing, though insurance coverage for compounded medications is inconsistent.

Telehealth Prescribing of Vyvanse in South Dakota

South Dakota permits telehealth prescribing of Schedule II controlled substances, including Vyvanse. The state's telehealth regulations, updated during the COVID-19 public health emergency and subsequently made permanent through SB 82 (signed into law in 2023), allow prescribers licensed in South Dakota to evaluate and prescribe controlled substances via audio-video telehealth visits [9].

Federal rules still apply. The DEA's telemedicine prescribing flexibilities, extended through 2025 and proposed for further extension into 2026, require a real-time audio-video evaluation for initial Schedule II prescriptions [10]. A phone-only visit is not sufficient for a new Vyvanse prescription.

Wigal et al. (2017) demonstrated in a randomized controlled trial that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV total scores compared to placebo in children and adolescents (effect size d = 0.80, P<0.001), confirming the clinical value of the medication that patients are seeking to access through telehealth channels [11]. Ensuring access via telehealth becomes especially relevant in South Dakota, where the nearest in-person psychiatrist may be 100 miles or more from rural communities.

Several national telehealth ADHD platforms (Done, Cerebral, Ahead) operate in South Dakota, though patients should verify that their specific telehealth provider is licensed in the state and that the prescriber has Schedule II prescribing authority. South Dakota requires that telehealth prescribers of controlled substances establish a bona fide clinician-patient relationship, which the initial video evaluation satisfies.

Dr. Lenard Adler, Director of the Adult ADHD Program at NYU Langone Health, has observed: "Telehealth has meaningfully expanded ADHD diagnosis and treatment access in rural states, but appropriate safeguards for controlled substance prescribing remain necessary" [6]. South Dakota's regulatory framework attempts to balance these concerns.

How to Pay the Least for Vyvanse in South Dakota

The lowest-cost path for most South Dakota patients in 2026 is generic lisdexamfetamine filled at a retail pharmacy using a discount coupon or low-tier insurance copay. Here is a practical breakdown by situation:

Commercially insured, generic covered at Tier 2: Fill generic lisdexamfetamine at your preferred pharmacy. Expected cost: $15 to $50 per month.

Commercially insured, only brand covered or high copay: Ask your prescriber to write "DAW" for brand Vyvanse and apply the Takeda savings card. Expected cost: $30 per month up to the annual card maximum.

Uninsured or underinsured: Fill generic lisdexamfetamine at Costco (no membership required for pharmacy in South Dakota), Walmart, or Hy-Vee with a GoodRx or RxSaver coupon. Expected cost: $25 to $45 per month.

South Dakota Medicaid enrolled: Request prior authorization through your prescriber. If denied, fill generic lisdexamfetamine at cash-pay pricing (often cheaper than the Medicaid copay for non-preferred drugs would be, if it were covered). Alternatively, ask your prescriber about formulary-preferred alternatives such as generic mixed amphetamine salts.

Pediatric patient who cannot swallow capsules: Vyvanse capsules can be opened and the powder dissolved in water or yogurt per the FDA-approved labeling [2]. This avoids the need for a compounded liquid formulation and its associated cost.

Patients filling at independent pharmacies in rural South Dakota should call ahead to confirm stock. Periodic generic lisdexamfetamine supply disruptions have occurred since 2023 due to DEA manufacturing quotas for Schedule II stimulants, and smaller pharmacies may not maintain consistent inventory [10].